| |
| |
|
| Insider
Information: |
Squinto Stephen P |
| Relationship: |
Director, 10% Owner |
| City: |
Cheshire |
| State: |
CT |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
238,160 |
|
|
Indirect Shares
|
6,290,493 |
|
|
| Direct
Value |
$19,437,710 |
|
|
|
Indirect Value
|
$19,013,945 |
|
|
| Total
Shares |
6,528,653 |
|
|
| Total
Value |
$38,451,655 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Alexion Pharmaceuticals Inc |
ALXN |
EVP, Chief Global Ops.... |
2014-10-27 |
106,508 |
2013-10-28 |
104,186 |
Premium* |
|
|
Springworks Therapeutics, Inc. |
SWTX |
Director, 10% Owner |
2022-05-19 |
131,652 |
2022-05-19 |
6,186,307 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SWTX |
Springworks Therapeutics,... |
Director |
– • • |
2019-09-17 |
4 |
A |
$0.00 |
$0 |
I/I |
7,131,307 |
7,131,307 |
0 |
- |
|
| SWTX |
Springworks Therapeutics,... |
Director |
– • • |
2019-09-17 |
4 |
B |
$18.00 |
$4,950,000 |
I/I |
275,000 |
7,406,307 |
2.25 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2012-07-27 |
4 |
AS |
$105.86 |
$10,800,149 |
D/D |
(100,668) |
86,994 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2012-07-27 |
4 |
OE |
$17.98 |
$2,096,280 |
D/D |
100,000 |
187,662 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
• – – |
2005-05-02 |
4 |
AS |
$20.32 |
$1,189,127 |
D/D |
(57,343) |
4,000 |
|
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2012-02-17 |
4 |
OE |
$11.92 |
$945,048 |
D/D |
55,260 |
142,922 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2012-02-17 |
4 |
S |
$81.27 |
$4,495,938 |
D/D |
(55,260) |
87,662 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2011-10-24 |
4 |
S |
$68.84 |
$3,654,394 |
D/D |
(52,740) |
78,851 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2011-10-24 |
4 |
OE |
$11.92 |
$628,661 |
D/D |
52,740 |
131,591 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2012-06-06 |
4 |
S |
$90.00 |
$4,500,000 |
D/D |
(50,000) |
87,662 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2012-06-06 |
4 |
OE |
$17.65 |
$882,500 |
D/D |
50,000 |
137,662 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2012-07-09 |
4 |
OE |
$17.98 |
$899,000 |
D/D |
50,000 |
137,662 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2012-07-09 |
4 |
AS |
$100.34 |
$5,021,772 |
D/D |
(50,000) |
87,662 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
• – – |
2005-05-02 |
4 |
OE |
$10.00 |
$450,000 |
D/D |
45,000 |
61,343 |
|
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Global Ops. Officer |
• – – |
2013-07-01 |
4 |
OE |
$22.90 |
$1,726,762 |
D/D |
44,125 |
152,587 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Global Ops. Officer |
• – – |
2013-07-01 |
4 |
AS |
$94.34 |
$4,190,622 |
D/D |
(44,125) |
108,462 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Global Ops. Officer |
• – – |
2013-10-28 |
4 |
S |
$124.06 |
$4,967,340 |
D/D |
(40,037) |
105,186 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Global Ops. Officer |
• – – |
2013-10-28 |
4 |
OE |
$78.88 |
$3,271,739 |
D/D |
40,037 |
145,223 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Global Ops. Officer |
• – – |
2013-04-29 |
4 |
OE |
$22.90 |
$1,231,027 |
D/D |
36,499 |
144,961 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Global Ops. Officer |
• – – |
2013-04-29 |
4 |
AS |
$98.96 |
$3,612,051 |
D/D |
(36,499) |
108,462 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Global Ops. Officer |
• – – |
2014-02-04 |
4 |
S |
$153.63 |
$5,603,781 |
D/D |
(36,137) |
94,818 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research & Devel |
• – – |
2008-05-19 |
4 |
OE |
$10.74 |
$627,956 |
D/D |
35,827 |
51,728 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research & Devel |
• – – |
2008-05-19 |
4 |
AS |
$69.72 |
$2,501,336 |
D/D |
(35,827) |
15,901 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
• – – |
2007-11-05 |
4 |
AS |
$75.03 |
$2,625,900 |
D/D |
(34,998) |
13,772 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
• – – |
2011-01-18 |
4 |
AS |
$82.66 |
$2,919,280 |
D/D |
(34,346) |
34,247 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
